XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - Lilly (Details) - Eli Lilly - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 160 Months Ended
Mar. 31, 2022
May 31, 2019
Dec. 31, 2009
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2016
OLUMIANT Royalty Revenues | Non-US              
License Agreements              
Royalties payable on net sales       $ 34.2 $ 48.1    
Development Milestones              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           $ 149.0  
Development Milestones | Maximum              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement     $ 150.0        
Regulatory Milestones              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           335.0  
Regulatory Milestones | GVHD              
License Agreements              
Milestone payment made under license agreement   $ 20.0          
Regulatory Milestones | GVHD | Europe              
License Agreements              
Milestone payment made under license agreement $ 20.0            
Regulatory Milestones | Maximum              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement     365.0        
Regulatory Milestones | Maximum | GVHD              
License Agreements              
Additional milestone payments under the license agreement             $ 40.0
Commercialization Milestones              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           $ 50.0  
Commercialization Milestones | Maximum              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement     $ 150.0